A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621 a Novel Biologic Targeting CD47 in Subjects with Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
